BGNE - BeiGene, Ltd.
| Previous Close | 134.35 |
| Open | 133.95 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 133.45 - 136.65 |
| 52 Week Range | 105.19 - 220.10 |
| Volume | 127,420 |
| Avg. Volume | 366,371 |
| Market Cap | 8.147B |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.15 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 190.82 |
- MarketWatch•13 days ago
Be cautious about the market now — and buy these 3 stocks on weakness
It's time to get a bit more cautious about stocks now for two reasons: Investor sentiment has ramped up and the markets are overbought. Virtually all of the dozen or so sentiment indicators I track were recently either neutral or bearish. One saving grace for the bulls is that the Investors Intelligence Bull/Bear ratio, a key indicator I track, has recently hovered around 2.57.
- Reuters•16 days ago
BRIEF-Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics
March 6 (Reuters) - Beigene Ltd: * AMBRX AND BEIGENE ANNOUNCE GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION TO DEVELOP NEXT-GENERATION BIOLOGICS * BEIGENE LTD - UNDER TERMS, AMBRX WILL RECEIVE AN UPFRONT ...
- GlobeNewswire•16 days ago
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
Ambrx to receive an upfront payment of US$10 million to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates in this collaboration.
- GlobeNewswire•17 days ago
Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson — Fundamental Analysis, Key Performance Indications
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- GlobeNewswire•18 days ago
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of BGNE earnings conference call or presentation 27-Feb-19 11:00pm GMT
Q4 2018 Beigene Ltd Earnings Call
- Zacks•21 days ago
Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.
- Zacks•21 days ago
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.
- Zacks•22 days ago
Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat
Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.
- Reuters•22 days ago
BRIEF-Beigene Reports Qtrly Loss Per Share Of $0.35
Feb 27 (Reuters) - Beigene Ltd: * BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS * BEIGENE LTD QTRLY NET LOSS PER ADS ATTRIBUTABLE TO BEIGENE LTD $4.52 * BEIGENE LTD QTRLY LOSS PER ...
- GlobeNewswire•22 days ago
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT CAMBRIDGE, Mass. and BEIJING, China,.
- ACCESSWIRE•22 days ago
BeiGene Ltd. Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2019 / BeiGene Ltd. Sponsored ADR (NASDAQ: BGNE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 27, 2019 ...
- GlobeNewswire•28 days ago
BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Simply Wall St.•29 days ago
Have Insiders Been Selling BeiGene, Ltd. (NASDAQ:BGNE) Shares?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We often see insiders buying up shares in companies thatRead More...
- GlobeNewswire•last month
BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
Zanubrutinib was discovered by BeiGene scientists and is being developed globally as a monotherapy and in combination with other therapies to treat various hematologic malignancies. Zanubrutinib is being studied in several clinical trials as part of a broad development program and was granted Breakthrough Therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and Fast Track designation for the treatment of patients with Waldenström macroglobulinemia (WM) by the U.S. Food and Drug Administration (FDA).
- GlobeNewswire•last month
Market Trends Toward New Normal in CenturyLink, Textainer Group, BeiGene, Nova Measuring Instruments, One Liberty Properties, and Westwood Holdings Group — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Zacks•last month
BeiGene, Ltd. (BGNE) Upgraded to Strong Buy: Here's What You Should Know
BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•last month
BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong
CAMBRIDGE, Mass., and BEIJING, China, Feb. 13, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•last month
BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day
CAMBRIDGE, Mass., and BEIJING, China, Feb. 07, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Zacks•2 months ago
BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know
Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.
GuruFocus.com•2 months ago6 Stocks Beating the Market
According to the GuruFocus All-in-One Guru Screener, the following stocks have outperformed the Standard & Poor's 500 index over the past 12 months and were bought by gurus during the third quarter. Warning! GuruFocus has detected 6 Warning Signs with BGNE. The share price is 50.86% above its 52-week low and 34.65% below its 52-week high.
- Reuters•2 months ago
BRIEF-Beigene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib
Jan 15 (Reuters) - Beigene Ltd: * RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZANUBRUTINIB IN MANTLE CELL LYMPHOMA Source text for Eikon: Further company coverage:
- MarketWatch•2 months ago
BeiGene drug gets 'breakthrough therapy' designation from FDA
U.S. shares of BeiGene Ltd. rose in the extended session Monday after the biotech drug developer said the Food and Drug Administration will expedite the regulatory process for one of its drugs. BeiGene ADRs rose 4% after hours, following a 4.6% decline to close at $137.55 Monday. The company said the FDA gave a "Breakthrough Therapy" designation to its mantle cell lymphoma treatment, meaning the experimental drug zanubrutinib will get expedited review and guidance from the agency.
- GlobeNewswire•2 months ago
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Barrons.com•2 months ago
Engaged Capital Helps Rethink Benchmark Electronics
The goal is to turn the manufacturer into a designer, developer, and value-added partner. Plus, news on 10 other investors’ filings.
